Dashboard
1
With a growth in Net Profit of 1524.43%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 5.68%
- RAW MATERIAL COST(Y) Fallen by -197.79% (YoY)
- NET SALES(Q) Highest at CNY 703.53 MM
2
With ROE of 5.51%, it has a very attractive valuation with a 0.99 Price to Book Value
3
Market Beating Performance
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
39.63%
0%
39.63%
6 Months
26.47%
0%
26.47%
1 Year
87.12%
0%
87.12%
2 Years
113.81%
0%
113.81%
3 Years
-9.66%
0%
-9.66%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.91%
EBIT Growth (5y)
-16.28%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.36
Tax Ratio
12.27%
Dividend Payout Ratio
16.67%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.26%
ROE (avg)
10.19%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
0.99
EV to EBIT
15.18
EV to EBITDA
9.54
EV to Capital Employed
0.99
EV to Sales
1.80
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
6.52%
ROE (Latest)
5.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
703.50
433.50
62.28%
Operating Profit (PBDIT) excl Other Income
155.80
54.80
184.31%
Interest
2.60
3.10
-16.13%
Exceptional Items
1.50
3.70
-59.46%
Consolidate Net Profit
144.20
8.80
1,538.64%
Operating Profit Margin (Excl OI)
221.40%
11.10%
21.03%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 62.28% vs 1.74% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 1,538.64% vs -71.79% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,936.90
1,769.50
9.46%
Operating Profit (PBDIT) excl Other Income
323.40
214.90
50.49%
Interest
15.40
13.70
12.41%
Exceptional Items
2.80
5.40
-48.15%
Consolidate Net Profit
117.60
51.50
128.35%
Operating Profit Margin (Excl OI)
61.00%
18.60%
4.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 9.46% vs -13.72% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 128.35% vs -40.94% in Dec 2024
About Hubei Hongyuan Pharmaceutical Technology Co., Ltd. 
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
Specialty Chemicals
No Details Available.
Company Coordinates 
No Company Details Available






